PTN Post | Issue 34

Issue 34 | May 2021

Hello,

As Spring moves forward and Summer approaches, the Pediatric Trials Network continues its commitment to studying the safety and efficacy of drugs and medical devices used in pediatric patients.

With May being Mental Health Awareness Month, we observe the way the network has responded to the needs of pediatric mental health. We are continuing our response to the COVID-19 pandemic by investigating ways to treat pediatric cases of SARS-CoV-2 infection and related illnesses. This issue will share some of those highlights with you, below.

As always, thank you for your commitment to the PTN.

Danny Benjamin, MD, PhD, MPH

Pediatric Trials Network, Principal Investigator

Kanecia Zimmerman, MD

Pediatric Trials Network, Steering Committee Chair

PTN's COVID-19 Response

PTN remains committed to playing an active role in the response to COVID-19. From studying multi-inflammatory syndrome (MIS-C) in children, to updating the existing POP02 study to include participants with COVID, PTN has played an integral role in COVID-19 research.

Learn more below:

PTN Partnership with iCAN

The 2021 iCAN Virtual Summit will be July 12-16th, 2021. This week-long event is designed for iCAN youth members, community leaders, and healthcare professionals to learn and share pediatric patient insight, and ways to further improve pediatric research. Register now at iCANResearch.org/2021-summit to receive fun conference materials.

PTN's strategic partnership with iCAN helps ensure the participant voice and perspective is considered in all the work performed by the network.

May is Mental Health Awareness Month

May is recognized as Mental Health Awareness Month as a way to bring awareness to the importance mental health and well-being. The PTN recognizes the significance of mental health on the developmental and cognitive health of children and adolescents. Through research efforts such as the Long-term Antipsychotic Pediatric Safety Trial (LAPS), the PTN continuously aims to find ways to safely and effectively treat pediatric patients and their medical conditions.

Learn More

POP02 Enrolls Participants in Record Speed

PTN's Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POP02) Study has activated new sites in record speed. The study structure previously put in place by PTN POPS served as the supporting framework and was helpful in PTN’s ability to establish a COVID-19-focused trial (POP02-COVID sub-study) more rapidly. The fast support of sites to expedite the activation process was paramount in getting the project off the ground.

Interested in

Participating in PTN Studies?

Currently enrolling:

Learn more about each study via the links below

Recruiting soon:

Safety, Preliminary Effectiveness, and Pharmacokinetics (PK) of Drugs in Infants (Infant Master Protocol)

Process for Sharing Data and Samples

Have you heard? PTN has a new process for requesting access to samples and/or data from its studies for additional testing. An investigator must access data and samples directly from the NIH Data and Specimen Hub (DASH). See the PTN Data Sharing page for more information.

Subscribe to the PTN Post here!

PTN is sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and provides pediatricians, researchers, and regulators with new information on how children respond to medications.